Riskpilot← Back to searchSign inGet full accessPHILIPS BIOCELL A/S
A/SDissolvedCVR 19738833Gydevang 42Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik · NACE 721900Est. 199726 employees
Revenue 2016
DKK 7,4M
-23% vs 2015
EBITDA margin
-441.0%
-152% vs 2015
Equity ratio
-64.8%
Financial strength
Net profit 2016
DKK -46M
-247% vs 2015
| Revenue | DKK 7,4M | -23% |
| EBITDA | DKK -32,6M | -152% |
| Net profit | DKK -46M | -247% |
| Total assets | DKK 15,3M | -79% |
| Equity | DKK -9,9M | -127% |
| Employees | 26 | — |
Legal name
PHILIPS BIOCELL A/S
CVR number
19738833
Legal form
Aktieselskab
NACE code
721900 · Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Founded
8. januar 1997
Share capital
DKK 797.586
Employees
26 (FTE)
VAT registered
No
Audit selected
No
Last report
2016-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to bestyrelsesmedlemmer i forening, af den administrerende direktør i forening med et medlem af bestyrelsen eller af den samlede bestyrelse.
Address
Gydevang 42
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2014 | 2015 | 2016 |
|---|---|---|---|---|---|---|
| Revenue | 12.662 | -15.413 | 18.127 | 72.047 | 9.581 | 7.389 |
| Staff expenses | -11.275 | -12.108 | -15.098 | -13.315 | -22.524 | -39.978 |
| EBITDA | 1.387 | -1.835 | 3.029 | 58.732 | -12.944 | -32.589 |
| Depreciation & amort. | 697 | -735 | -1.842 | -2.080 | -3.398 | -23.362 |
| EBIT | 690 | -2.570 | 1.188 | 56.652 | -16.341 | -55.951 |
| Net financials | -253 | 0 | -370 | -422 | -641 | -24 |
| Profit before tax | 437 | -2.386 | 818 | 56.231 | -16.982 | -55.975 |
| Tax | 121 | -611 | 179 | 13.408 | -3.734 | -10.017 |
| Net profit | 315 | -1.775 | 639 | 42.823 | -13.248 | -45.958 |
| Item | 2012 | 2013 | 2014 | 2014 | 2015 | 2016 |
|---|---|---|---|---|---|---|
| Total assets | 11.377 | 13.457 | 16.539 | 79.326 | 74.252 | 15.301 |
| Equity | 3.221 | 4.700 | 4.869 | 49.296 | 36.048 | -9.910 |
| Long-term debt | 30 | 0 | 0 | 5.680 | 0 | 0 |
| Short-term debt | 8.125 | -8.454 | 11.188 | 21.678 | 38.204 | 14.537 |
| Total debt | 8.156 | -8.454 | 11.188 | 27.358 | 38.204 | 14.537 |
EBITDA margin
-441.0%
This company
15.8%
Market median
-2891% vs market
20122016
Equity ratio
-64.8%
This company
38.2%
Market median
-270% vs market
20122016
Return on equity
-4595795500.0%
This company
18.4%
Market median
-24977149557% vs market
20122016
Net profit margin
-622.0%
This company
8.1%
Market median
-7779% vs market
20122016
Asset turnover
0.48×
This company
1.12×
Market median
-57% vs market
20122016
Debt / equity
2.54×
This company
0.62×
Market median
-310% vs market
20122016
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-04-01 – 2014-12-31
- Annual report 2014Filed via CVR / Virk · Period 2013-04-01 – 2014-03-31
- Annual report 2013Filed via CVR / Virk · Period 2012-04-01 – 2013-03-31
- Annual report 2012Filed via CVR / Virk · Period 2011-04-01 – 2012-03-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PS Management | Management | 1997 | — | — |
TO Management | Management | 1997 | — | — |
PD Management | Management | 1998 | — | — |
JE Chief Executive Officer | Chief Executive Officer | 2004 | — | — |
Mv Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2006 | — | — | |
| Board of Directors | 2014 | — | — | |
| Board of Directors | 2002 | — | — | |
| Board of Directors | 2016 | — | — | |
| Chairman | 2014 | — | — | |
| Board of Directors | 1997 | — | — | |
| Chairman | 2003 | — | — | |
| Deputy Chairman | 2014 | — | — | |
| Board of Directors | 2004 | — | — | |
| Board of Directors | 2008 | — | — | |
| Board of Directors | 2004 | — | — | |
| Board of Directors | 2002 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
PHILIPS DANMARK A/S | Company | 100.0% | 100.0% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of PHILIPS BIOCELL A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Poul Steen Hansen | Management | 0 companies |
| Tom Olesen | Management | 0 companies |
| Preben Damgård Jensen | Management | 0 companies |
| Jens Erik Haugaard | Chief Executive Officer | 0 companies |
| Marcel van Kasteel | Chief Executive Officer | 0 companies |
| Henning Ellesgaard | Board of Directors | 0 companies |
| Timorthy Raoul Ozinga | Board of Directors | 0 companies |
| Mette Nerstrøm Damgård Jensen | Board of Directors | 0 companies |
| Krishna Kumar Ananthasubramanian | Board of Directors | 0 companies |
| Lars Lokdam | Chairman | 0 companies |
| Leif Sørensen | Board of Directors | 0 companies |
| Lars Lading | Chairman | 0 companies |
| Russell Todd Granzow | Deputy Chairman | 0 companies |
| Henrik Mogens Stæhr-Olsen | Board of Directors | 0 companies |
| Svend Erik Licht | Board of Directors | 0 companies |
| Eivind Johansen | Board of Directors | 0 companies |
| Lis Hermann Olesen | Board of Directors | 0 companies |